Literature DB >> 34491786

Goals of Care and Patient-Centric Outcomes for Checkpoint Inhibitor Immunotherapy in Patients With Limited Performance Status.

Ryan C Augustin1, Jason J Luke1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34491786      PMCID： PMC8758124          DOI： 10.1200/OP.21.00552

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN： 2688-1527


× No keyword cloud information.
  11 in total

Review 1.  American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology.

Authors:  Lowell E Schnipper; Thomas J Smith; Derek Raghavan; Douglas W Blayney; Patricia A Ganz; Therese Marie Mulvey; Dana S Wollins
Journal:  J Clin Oncol       Date:  2012-04-03       Impact factor: 44.544

2.  Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial.

Authors:  Camilla Zimmermann; Nadia Swami; Monika Krzyzanowska; Breffni Hannon; Natasha Leighl; Amit Oza; Malcolm Moore; Anne Rydall; Gary Rodin; Ian Tannock; Allan Donner; Christopher Lo
Journal:  Lancet       Date:  2014-02-19       Impact factor: 79.321

3.  Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis.

Authors:  J L Pater; M Loeb
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860

4.  Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer.

Authors:  Tamjeed Ahmed; Thomas Lycan; Andy Dothard; Paul Ehrlichman; Jimmy Ruiz; Michael Farris; Umit Topaloglu; Beverly Levine; Stefan Grant; Heidi D Klepin; W Jeffrey Petty
Journal:  Clin Lung Cancer       Date:  2020-01-23       Impact factor: 4.785

5.  ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.

Authors:  Filippo G Dall'Olio; Ilaria Maggio; Maria Massucci; Veronica Mollica; Benedetta Fragomeno; Andrea Ardizzoni
Journal:  Lung Cancer       Date:  2020-05-06       Impact factor: 5.705

6.  Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.

Authors:  Juan C Osorio; Kathryn C Arbour; Dung T Le; Jennifer N Durham; Andrew J Plodkowski; Darragh F Halpenny; Michelle S Ginsberg; Peter Sawan; Joseph G Crompton; Helena A Yu; Azadeh Namakydoust; Barzin Y Nabet; Jamie E Chaft; Gregory J Riely; Hira Rizvi; Luis A Diaz; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2019-11-01       Impact factor: 44.544

7.  Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer.

Authors:  Chung-Shien Lee; Craig E Devoe; Xinhua Zhu; Joanna Stein Fishbein; Nagashree Seetharamu
Journal:  Lung Cancer Manag       Date:  2020-04-24

8.  Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.

Authors:  Ali Raza Khaki; Ang Li; Leonidas N Diamantopoulos; Mehmet A Bilen; Victor Santos; John Esther; Rafael Morales-Barrera; Michael Devitt; Ariel Nelson; Christopher J Hoimes; Evan Shreck; Hussein Assi; Benjamin A Gartrell; Alex Sankin; Alejo Rodriguez-Vida; Mark Lythgoe; David J Pinato; Alexandra Drakaki; Monika Joshi; Pedro Isaacsson Velho; Noah Hahn; Sandy Liu; Lucia Alonso Buznego; Ignacio Duran; Marcus Moses; Jayanshu Jain; Jure Murgic; Praneeth Baratam; Pedro Barata; Abhishek Tripathi; Yousef Zakharia; Matthew D Galsky; Guru Sonpavde; Evan Y Yu; Veena Shankaran; Gary H Lyman; Petros Grivas
Journal:  Cancer       Date:  2019-12-12       Impact factor: 6.921

9.  Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.

Authors:  Fang Yang; Svetomir N Markovic; Julian R Molina; Thorvardur R Halfdanarson; Lance C Pagliaro; Ashish V Chintakuntlawar; Rutian Li; Jia Wei; Lifeng Wang; Baorui Liu; Grzegorz S Nowakowski; Michael L Wang; Yucai Wang
Journal:  JAMA Netw Open       Date:  2020-08-03

10.  Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors.

Authors:  Mridula Krishnan; Pooja Kasinath; Robin High; Fang Yu; Benjamin A Teply
Journal:  JCO Oncol Pract       Date:  2021-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.